Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022724 · ClinicalTrials.gov registry record · Phase 1
CCI-779 in Treating Patients With Malignant Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00022724 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 49 participants.
The verdict
NCT00022724, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CCI-779 in treating patients who have malignant glioma.
Interventions
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2001-08-27 |
| Est. Completion | 2007-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022724
The ClinicalTrials.gov registry entry for NCT00022724 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which temsirolimus is the first listed.
NCT00022724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022724 about?
NCT00022724 is a clinical study titled "CCI-779 in Treating Patients With Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CCI-779 in treating patients who have malignant glioma.
What is the current status of trial NCT00022724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2001-08-27. Estimated completion is 2007-12-15.
What interventions are being tested in trial NCT00022724?
The interventions under investigation include: temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00022724?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.